标准及预激方案序贯双诱导治疗初治急性髓系白血病临床观察

Sequential bi-induction standard chemotherapy combined with priming chemotherapy in the treatment of patients with initial treatment acute myelocytic leukemia

目的观察标准化疗联合预激方案序贯双诱导治疗原发初治急性髓系白血病(AML)的疗效和安全性。方法对患者进行标准方案[蒽环类联合阿糖胞苷(Ara-C)]联合预激方案序贯诱导缓解治疗,治疗过程中监测治疗反应及化疗不良反应。结果 15例患者中完全缓解13例,完全缓解率为86.7%。最常见的不良反应为骨髓抑制,其次为感染,以肺部感染最常见(发生率为40.0%)。结论标准联合预激方案序贯双诱导治疗原发初治AML有效且安全。

Objective To observe the efficacy and safety of sequential bi-induction standard chemotherapy combined with priming chemotherapy in treating patients with initial treatment acute myelocytic leukemia（AML）. Methods Standard chemo- therapy（ anthracycline joint cytarabine）combined with priming chemotherapy was administered to patients with initial treatment AML, and the treatment response and side effects of chemotherapy were monitored. Results Among the 15 patients, 13 patients were CR（86. 7% ）. Bone marrow suppression were the most common adverse reactions in the treatment;The second was infec- tion, and the lung infection was the most common （ the incidence was 40. 0% ）. Conclusion Sequential bi-induction standard chemotherapy combined with priming chemotheragy is both effective and well tolerated in patients with initial treatment AML.